You can buy or sell AMPE and other stocks, options, ETFs, and crypto commission-free!
Ampio Pharmaceuticals, Inc, also called Ampio Pharmaceuticals, is a biopharmaceutical company, that engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation, sexual dysfunction and CNS disease. Read More The company was founded by David Bar-Or in April 2010 and is headquartered in Englewood, CO.
52 Week High
52 Week Low
PR NewswireMar 6
Ampio Updates Regulatory Status for Ampion
ENGLEWOOD, Colo., March 6, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today updates the regulatory status of Ampion™. Food and Drug Administration (FDA) provided guidance that Ampio should complete an additional trial of Kellgren Lawrence Grade 4 (KL 4) osteoarthritis of the knee (OAK) patients with concurrent controls that would be carried out under a Special Protocol Assessment (SPA). Ampio presented the FDA with two different forms of concurrent controls the company was considerin...
Yahoo FinanceFeb 25
Research Report Identifies Wolverine World Wide, Viking Therapeutics, Ampio Pharmaceuticals, ArcelorMittal, Delphi Technologies, and Unit with Renewed Outlook — Fundamental Analysis, Calculating Forwa
NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Wolverine World Wide, Inc. (WWW), Viking Therapeutics, Inc. (VKTX), Ampio Pharmaceuticals, Inc. (AMPE), ArcelorMittal (MT), Delphi Technologies PLC (DLPH), and Unit Corporation (UNT), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst ...
Stock Price, News, & Analysis for Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeabil...
Expected Mar 21, Pre-Market